Abstract 8806: Comparative Efficacy of GLP-1 Receptor Agonists versus SGLT-2 Inhibitors for Limb Outcomes in Patients with Peripheral Artery Disease: A Multicenter Propensity Score-Matched Real-World Study
Abstract
Background: Patients with peripheral artery disease (PAD) face high risks of limb loss, revascularization, and cardiovascular events. While both GLP-1 receptor agonists (GLP-1 RAs) and SGLT-2 inhibitors (SGLT-2is) improve cardiovascular outcomes in type 2 diabetes, their comparative effectiveness on limb-specific outcomes in broad PAD populations remains unclear. We compared GLP-1 RAs versus SGLT-2is on limb and cardiovascular outcomes in real-world patients with PAD. Methods: In this retrospective multicenter study using the TriNetX US Collaborative Network, adults with PAD (ICD-10-CM I73) who newly initiated a GLP-1 RA or SGLT-2i were identified. Patients with prior exposure to the comparator drug were excluded. Propensity score matching (1:1) was performed on 44 covariates including demographics, comorbidities, medications, and laboratory values. Outcomes from day 1 to 730 (upto 2-year) post-index included major lower-extremity amputation, chronic limb ischemia, endovascular revascularization, progression of extremity atherosclerosis, all-cause hospitalization, major adverse cardiovascular events (MACE), and all-cause mortality. Analyses used Kaplan-Meier estimates, Cox proportional hazards models, and multivariable adjustment. Results: Post-matching, cohorts comprised 51,995 patients per group for 1-year and 55,238 per group for 2-year analyses, achieving excellent covariate balance (standardized mean differences <0.10 for most variables). Compared with SGLT-2is, GLP-1 RAs were associated with significantly lower 1-year risks: all-cause mortality (4.53% vs 6.10%; HR 0.704, 95% CI 0.667-0.742), major amputation (1.15% vs 1.43%; HR 0.770, 95% CI 0.691-0.858), all-cause hospitalization (21.53% vs 30.22%; HR 0.644, 95% CI 0.628-0.660), MACE (11.24% vs 14.93%; HR 0.703, 95% CI 0.680-0.728), chronic limb ischemia (2.48% vs 2.63%; HR 0.907, 95% CI 0.840-0.978), endovascular revascularization (2.17% vs 2.70%; HR 0.770, 95% CI 0.712-0.833), and progression of extremity atherosclerosis (10.89% vs 12.54%; HR 0.829, 95% CI 0.800-0.859); all log-rank p<0.05. Similar relative risk reductions persisted at 2 years (mortality HR 0.772; amputation HR 0.816). In multivariable Cox regression adjusting for sex, CKD, diabetes, BMI, LVEF, and other factors, GLP-1 RA use remained independently associated with markedly lower mortality (adjusted HR 0.460, 95% CI 0.438-0.483, p<0.0001). Conclusions: In this large propensity score-matched real-world study of patients with PAD, GLP-1 RAs were associated with substantially lower risks of major limb events, revascularization, atherosclerotic progression, hospitalization, MACE, and mortality compared with SGLT-2is. These findings support the preferential consideration of GLP-1 RAs for vascular risk reduction in PAD, pending confirmation by randomized trials.